Is neurofilament light chain useful as a disease progression marker for ATTRv amyloidosis? A literature review

DOI Web Site PubMed 57 References
  • Sekijima Yoshiki
    Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine
  • Ueda Mitsuharu
    Department of Neurology, Graduate School of Medical Sciences, Kumamoto University
  • Takahashi Kentaro
    Medical Affairs, Alnylam Japan K.K.
  • Kitaoka Hiroaki
    Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University

Bibliographic Information

Other Title
  • ニューロフィラメント軽鎖は遺伝性ATTRアミロイドーシスの活動性マーカーとして有用か？―文献レビュー

Description

<p>ATTRv amyloidosis is an autosomal-dominant disorder characterized by mutations in the transthyretin (TTR) gene, systemic deposition of transthyretin amyloid fibrils, and progressive polyneuropathy. Current scoring systems developed for ATTRv amyloidosis to measure the severity of polyneuropathy are not sufficiently sensitive or are difficult to implement in daily practice. Results of phase 3 trials for oligonucleotide therapeutics and real-world evidence have shown that neurofilament light chain (NfL), a key structural component of axons, is a reliable blood biomarker for assessing disease progression and treatment response in patients with ATTRv amyloidosis with polyneuropathy. Because blood NfL levels can be affected by factors such as age, body mass index (BMI), and renal function, its significance in patient monitoring needs to be assessed carefully while considering the clinical characteristics of each patient.</p>

Journal

  • Rinsho Shinkeigaku

    Rinsho Shinkeigaku 65 (4), 251-259, 2025

    Societas Neurologica Japonica

References(57)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top